Instrument Inactif

Communiqués Ayala Pharmaceuticals, Inc.

Actions

ADXS

US0076244062

Recherche biotechnologique et médicale

Communiqués

09/05/24	Ayala Pharmaceuticals Files Form 15 to Voluntarily Deregister and Suspend its Reporting Obligations	AQ
26/03/24	Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome	AQ
20/02/24	Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors	AQ
06/02/24	Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals	AQ
06/11/23	Ayala Pharmaceuticals Announces AL102 Receives Orphan Drug Designation for Desmoid Tumors	AQ
23/10/23	Ayala Pharmaceuticals Presents Updated AL102 Results from Phase 2 Clinical Trial in Desmoid Tumors at ESMO Congress 2023	AQ
19/10/23	Ayala Pharmaceuticals Announces Closing of Merger with Biosight	AQ
10/08/23	Ayala Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Corporate Update	AQ
01/08/23	Ayala Pharmaceuticals Announces Abstracts on AL102 and AL101 Accepted for Presentation at ESMO Congress 2023	AQ
27/07/23	Ayala Pharmaceuticals and Biosight Enter into Definitive Merger Agreement	AQ
05/07/23	Ayala Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA Regarding AL102 for the Treatment of Desmoid Tumors	AQ
05/06/23	Updated RINGSIDE Phase 2 Results Featured in Poster Discussion Session at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting	AQ
25/05/23	Ayala Pharmaceuticals Announces Updated RINGSIDE Phase 2 Results at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting	AQ
23/05/23	Ayala Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Corporate Update	AQ
27/04/23	Ayala Pharmaceuticals Announces RINGSIDE Results to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting	AQ
07/04/23	AYALA PHARMACEUTICALS, INC. : Changes in Registrant's Certifying Accountant (form 8-K)	AQ
06/04/23	AYALA PHARMACEUTICALS, INC. Financial Statements and Exhibits (form 8-K/A)	AQ
03/03/23	Ayala Pharmaceuticals Announces Continuation of RINGSIDE Phase 2/3 Study in Desmoid Tumors Following Recommendation of Independent Data Monitoring Committee	GL
10/02/23	Ayala Pharmaceuticals Reports Financial Results For the Fiscal Year Ended October 31, 2022	GL
10/02/23	AYALA PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	AQ
30/01/23	Advaxis : Certificate of Incorporation/Bylaws - Form 8-K	PU
30/01/23	AYALA PHARMACEUTICALS, INC. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year (form 8-K)	AQ
25/01/23	AYALA PHARMACEUTICALS, INC. : Completion of Acquisition or Disposition of Assets, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	AQ
13/01/23	ADVAXIS, INC. : Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure (form 8-K)	AQ
12/01/23	ADVAXIS, INC. : Other Events (form 8-K)	AQ